NO20024924L - Anvendelse av bradykardiale substanser ved behandling av myokardiale sykdommer i forbindelse med hypertrofi og nyemedikamentkombinasjoner - Google Patents

Anvendelse av bradykardiale substanser ved behandling av myokardiale sykdommer i forbindelse med hypertrofi og nyemedikamentkombinasjoner

Info

Publication number
NO20024924L
NO20024924L NO20024924A NO20024924A NO20024924L NO 20024924 L NO20024924 L NO 20024924L NO 20024924 A NO20024924 A NO 20024924A NO 20024924 A NO20024924 A NO 20024924A NO 20024924 L NO20024924 L NO 20024924L
Authority
NO
Norway
Prior art keywords
hypertrophy
bradycardial
substances
treatment
connection
Prior art date
Application number
NO20024924A
Other languages
English (en)
Other versions
NO330311B1 (no
NO20024924D0 (no
Inventor
Juergen Dommgen
Brian Guth
Randolph Seidler
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Publication of NO20024924D0 publication Critical patent/NO20024924D0/no
Publication of NO20024924L publication Critical patent/NO20024924L/no
Publication of NO330311B1 publication Critical patent/NO330311B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NO20024924A 2000-04-13 2002-10-11 Bradykardiale substanser for behandling av myokardiale sykdommer som ledsages av hypertrofi. NO330311B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10018401A DE10018401A1 (de) 2000-04-13 2000-04-13 Verwendung von Bradycardica bei der Behandlung von mit Hypertrophie einhergehenden Myocarderkrankungen und neue Arzneimittelkombinationen
PCT/EP2001/004034 WO2001078699A2 (de) 2000-04-13 2001-04-07 Verwendung von bradycardica bei der behandlung von mit hypertrophie einhergehenden myocarderkrankungen und neue arzneimittelkombinationen

Publications (3)

Publication Number Publication Date
NO20024924D0 NO20024924D0 (no) 2002-10-11
NO20024924L true NO20024924L (no) 2002-10-11
NO330311B1 NO330311B1 (no) 2011-03-28

Family

ID=7638652

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20024924A NO330311B1 (no) 2000-04-13 2002-10-11 Bradykardiale substanser for behandling av myokardiale sykdommer som ledsages av hypertrofi.

Country Status (33)

Country Link
US (2) US7208508B2 (no)
EP (2) EP1276476B1 (no)
JP (1) JP3905386B2 (no)
KR (1) KR20020089453A (no)
CN (1) CN1245963C (no)
AT (1) ATE330588T1 (no)
AU (2) AU2001270484B2 (no)
BG (1) BG65816B1 (no)
BR (1) BR0109996A (no)
CA (2) CA2575059A1 (no)
CY (1) CY1105081T1 (no)
CZ (1) CZ300549B6 (no)
DE (2) DE10018401A1 (no)
DK (1) DK1276476T3 (no)
EA (1) EA006977B1 (no)
EE (1) EE05099B1 (no)
ES (1) ES2266216T3 (no)
HR (1) HRP20020815A2 (no)
HU (1) HU228387B1 (no)
IL (2) IL152103A0 (no)
ME (1) MEP45908A (no)
MX (1) MXPA02009935A (no)
NO (1) NO330311B1 (no)
NZ (1) NZ521934A (no)
PL (1) PL215235B1 (no)
PT (1) PT1276476E (no)
RS (1) RS51478B (no)
SI (1) SI1276476T1 (no)
SK (1) SK286075B6 (no)
TR (1) TR200202326T2 (no)
UA (1) UA78679C2 (no)
WO (1) WO2001078699A2 (no)
ZA (1) ZA200208162B (no)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10018401A1 (de) * 2000-04-13 2001-10-25 Boehringer Ingelheim Pharma Verwendung von Bradycardica bei der Behandlung von mit Hypertrophie einhergehenden Myocarderkrankungen und neue Arzneimittelkombinationen
US20040138306A1 (en) * 2002-07-25 2004-07-15 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of a specific cyclic amine derivative or the pharmaceutically acceptable salts thereof for the treatment or prevention of heart failure
DE60200160T2 (de) * 2002-07-25 2004-11-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von Cilobradine oder pharmazeutisch akzeptablen Salze zur Behandlung oder Prävention von Herzversagen
EP1604664A4 (en) * 2003-01-31 2006-12-27 Sankyo Co MEDICAMENT FOR THE PREVENTION AND TREATMENT OF ARTERIOSCLEROSIS AND BLOOD HIGH PRESSURE
ES2404939T3 (es) * 2005-06-27 2013-05-29 Daiichi Sankyo Company, Limited Preparación farmacéutica que contiene un antagonista del receptor de la angiotensina II y un bloqueador de los canales de calcio
CA2617519A1 (en) * 2005-08-23 2007-03-01 Astellas Pharma Inc. Agent for treating atrial fibrillation
EP1762179A1 (en) * 2005-09-07 2007-03-14 Boehringer Ingelheim Vetmedica Gmbh Method for improving diagnostic quality in echocardiography
FR2894825B1 (fr) * 2005-12-21 2010-12-03 Servier Lab Nouvelle association d'un inhibiteur du courant if sinusal et d'un inhibiteur de l'enzyme de conversion et les compositions pharmaceutiques qui la contiennent
TWI399223B (zh) * 2006-09-15 2013-06-21 Daiichi Sankyo Co Ltd 奧美沙坦酯及氨氯地平之固體劑型
EP1908469A1 (en) * 2006-10-06 2008-04-09 Boehringer Ingelheim Vetmedica Gmbh Angiotensin II receptor antagonist for the treatment of systemic diseases in cats
CA2761576C (en) 2009-05-20 2017-08-22 Boehringer Ingelheim Vetmedica Gmbh Oral suspension comprising telmisartan
FR2961105B1 (fr) * 2010-06-15 2013-02-08 Servier Lab Utilisation de l'association d'un inhibiteur du courant if sinusal et d'un inhibiteur de l'enzyme de conversion de l'angiotensine pour le traitement de l'insuffisance cardiaque
KR101296743B1 (ko) * 2011-02-17 2013-08-20 한국과학기술연구원 심근 비대증 진단용 바이오마커 및 이를 이용한 심근 비대증 진단 방법
RU2014109079A (ru) 2011-08-12 2015-09-20 Бёрингер Ингельхайм Ветмедика Гмбх Фармацевтическая композиция с маскированным вкусом
EP2953612A1 (en) 2013-02-11 2015-12-16 Boehringer Ingelheim Vetmedica GmbH Kit-of-parts
AU2018295387B2 (en) 2017-07-07 2024-02-15 Boehringer Ingelheim Vetmedica Gmbh Angiotensin II receptor antagonist for the prevention or treatment of systemic diseases in cats
KR102398532B1 (ko) 2020-07-20 2022-05-13 한림대학교 산학협력단 중증 지주막하출혈 진단용 조성물
KR102331806B1 (ko) 2020-07-20 2021-12-01 한림대학교 산학협력단 중증 지주막하출혈 진단용 바이오 마커

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE759125A (fr) 1969-11-19 1971-05-18 Boehringer Sohn Ingelheim Nouvelles n-allyl-2-arylamino-imidazolines-(2) substituees et procedes pour les fabriquer
DE3119874A1 (de) 1981-05-19 1982-12-09 Dr. Karl Thomae Gmbh, 7950 Biberach "benzazepinderivate, ihre herstellung und ihre verwendung als arzneimittel"
US5175157A (en) * 1985-11-27 1992-12-29 Boehringer Ingelheim Gmbh Cyclic amine derivatives, pharmaceutical compositions containing these compounds and methods for preparing them
DE3541811A1 (de) * 1985-11-27 1987-06-04 Thomae Gmbh Dr K Neue cyclische aminderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
DE3736866A1 (de) * 1987-10-30 1989-05-11 Thomae Gmbh Dr K Mittel zur behandlung des bluthochdrucks und der herzinsuffizienz
DE3805635A1 (de) 1988-02-24 1989-09-07 Thomae Gmbh Dr K Verwendung von benzimidazolen zur herstellung eines arzneimittels mit antiischaemischen wirkungen am herzen und dessen kombinationen mit ss-blockern oder bradycardica
US5308853A (en) * 1991-12-20 1994-05-03 Warner-Lambert Company Substituted-5-methylidene hydantoins with AT1 receptor antagonist properties
RU2078536C1 (ru) * 1993-09-02 1997-05-10 Украинский научно-исследовательский институт кардиологии им.акад.Н.Д.Стражеско Способ определения клинической эффективности применения верапамила и дилтиазема у больных гипертрофической кардиомиопатией
CA2172497A1 (en) * 1993-09-24 1995-03-30 Song Liu Novel deoxy and oxygen-substituted sugar-containing 14-aminosteroid compounds
US5595987A (en) * 1994-07-22 1997-01-21 The Trustees Of Columbia University In The City Of New York Method of slowing ventricular arrhythmias using zatebradine
US6083991A (en) * 1997-06-04 2000-07-04 University Of Florida Research Foundation, Inc. Anti-arrhythmic composition and methods of treatment
DE19741635A1 (de) * 1997-09-22 1999-03-25 Hoechst Marion Roussel De Gmbh Biphenylsulfonylcyanamide, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament
CN1234357C (zh) * 1998-07-10 2006-01-04 诺瓦提斯公司 缬沙坦和钙通道阻断剂的抗超敏组合
DE10018401A1 (de) 2000-04-13 2001-10-25 Boehringer Ingelheim Pharma Verwendung von Bradycardica bei der Behandlung von mit Hypertrophie einhergehenden Myocarderkrankungen und neue Arzneimittelkombinationen
CA2435526A1 (en) 2002-07-25 2004-01-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of cyclic amine derivatives or the pharmaceutically acceptable salts thereof for the treatment or prevention of heart failure
US20040138306A1 (en) * 2002-07-25 2004-07-15 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of a specific cyclic amine derivative or the pharmaceutically acceptable salts thereof for the treatment or prevention of heart failure
EP1762179A1 (en) * 2005-09-07 2007-03-14 Boehringer Ingelheim Vetmedica Gmbh Method for improving diagnostic quality in echocardiography

Also Published As

Publication number Publication date
SK14582002A3 (sk) 2003-03-04
NZ521934A (en) 2007-05-31
TR200202326T2 (tr) 2003-03-21
HU228387B1 (en) 2013-03-28
IL152103A0 (en) 2003-07-31
SK286075B6 (sk) 2008-03-05
HUP0300917A2 (hu) 2003-08-28
SI1276476T1 (sl) 2006-10-31
BG65816B1 (bg) 2010-01-29
EP1666042A3 (de) 2006-06-21
IL152103A (en) 2008-07-08
EP1666042A2 (de) 2006-06-07
US7208508B2 (en) 2007-04-24
CN1245963C (zh) 2006-03-22
ATE330588T1 (de) 2006-07-15
NO330311B1 (no) 2011-03-28
JP2003535050A (ja) 2003-11-25
CN1422153A (zh) 2003-06-04
MEP45908A (en) 2011-02-10
WO2001078699A2 (de) 2001-10-25
DK1276476T3 (da) 2006-08-14
US20040014795A1 (en) 2004-01-22
PL215235B1 (pl) 2013-11-29
CZ300549B6 (cs) 2009-06-10
NO20024924D0 (no) 2002-10-11
CA2575059A1 (en) 2001-10-25
KR20020089453A (ko) 2002-11-29
PT1276476E (pt) 2006-09-29
US20070155679A1 (en) 2007-07-05
MXPA02009935A (es) 2003-02-12
CA2404120C (en) 2008-01-22
WO2001078699A3 (de) 2002-06-20
EP1276476A2 (de) 2003-01-22
ZA200208162B (en) 2003-10-17
EA006977B1 (ru) 2006-06-30
EP1276476B1 (de) 2006-06-21
DE10018401A1 (de) 2001-10-25
DE50110262D1 (de) 2006-08-03
AU2001270484B2 (en) 2007-01-25
RS51478B (sr) 2011-04-30
BG107103A (bg) 2003-04-30
HUP0300917A3 (en) 2009-04-28
CZ20023752A3 (cs) 2003-03-12
JP3905386B2 (ja) 2007-04-18
EE05099B1 (et) 2008-12-15
EA200201053A1 (ru) 2003-02-27
HRP20020815A2 (en) 2004-12-31
CA2404120A1 (en) 2001-10-25
PL357827A1 (en) 2004-07-26
BR0109996A (pt) 2003-05-27
YU76902A (sh) 2006-05-25
UA78679C2 (en) 2007-04-25
AU7048401A (en) 2001-10-30
EE200200590A (et) 2004-04-15
CY1105081T1 (el) 2009-11-04
ES2266216T3 (es) 2007-03-01

Similar Documents

Publication Publication Date Title
NO20024924D0 (no) Anvendelse av bradykardiale substanser ved behandling av myokardiale sykdommer i forbindelse med hypertrofi og nyemedikamentkombinasjoner
ES2164040T1 (es) Uso de agonistas del sitio de union de la glicina o de inhibidores de la absorcion de la glicina para el tratamiento de trastornos neuropsiquiatricos.
BRPI0108977B8 (pt) compostos azacíclicos, composição farmacêutica e uso de um composto ou sal farmaceuticamente aceitável do mesmo
EA200501496A1 (ru) Высокоселективные ингибиторы обратного захвата норэпинефрина и способы их применения
PT1900362E (pt) Derivados de alfa-aminoamida úteis no tratamento de perturbações aditivas
TW200505900A (en) Muscarinic agonists
NO2012015I2 (no) Dapoxetine
BR9910899A (pt) Compostos de ácido sulfÈnico ou sulfonilamino n-(hetero-aralquil)-azaeterocicliamida
WO2002034267A8 (de) Kombination eines transdermalen therapeutischen systems und einer oralen und/oder parenteralen zubereitung enthaltend dopaminagonisten zur behandlung dopaminerger erkrankungen
BR0111982A (pt) Tratamento com apomorfina, de disfunção sexual induzida por droga anti depressão
BR0108261A (pt) Uso de mirtazapina, método de tratamento de um distúrbio do sono em um indivìduo, e, kit para paciente para o tratamento de distúrbios do sono
NO20005223L (no) Sammensetning for og behandling av inflammatrisk tarmsykdom ved administrering av N-acetylglucosamin i tykktarmen
HK1064036A1 (en) Kapp-opiate agonists for the treatment of bladder dieseases
US6214849B1 (en) Use of nicorandil in treatment of sexual dysfunction or for enhancement of sexual function in mammals including humans
BRPI0414112A (pt) uso de oxcarbazepina para o tratamento de dor neuropática diabética e a melhora do sono
EP1632235A3 (en) Use of highly selective norepinephrine reuptake inhibitors for the treatment of mental disorders
PL1514545T3 (pl) Zastosowanie tolperyzonu do leczenia skurczów narządów zbudowanych zasadniczo z mięśni gładkich
Higgins Reducing GI toxicity of NSAIDs: common goal, different approaches
ECSP003771A (es) Metodo para prevenir la diarrea

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees